Diar Cancer Research Results
Diar, Diarrhea: Click to Expand ⟱
| Source: |
| Type: |
Diarrhea often chemotherapy induced
|
Scientific Papers found: Click to Expand⟱
Diar↓, Probiotic use was associated with a significant reduction in the incidence of diarrhea
*Inflam↓, anticancer, anti-edema, anti-inflammatory, anti-microbial, anti-coagulant, anti-osteoarthritis, anti-trauma pain, anti-diarrhea, wound repair.
*Bacteria↓,
*Pain↓,
*Diar↓,
*Wound Healing↑,
ERK↓, Figure 1
JNK↓,
XIAP↓,
HSP27↓,
β-catenin/ZEB1↓,
HO-1↓,
lipid-P↓,
ACSL4↑,
ROS↑,
SOD↑,
Catalase↓,
GSH↓,
MDA↓,
Casp3↓,
Casp9↑,
DNAdam↑,
Apoptosis↑,
NF-kB↓,
P53↑,
MAPK↓,
APAF1↑,
Cyt‑c↓,
CD44↓,
Imm↑, Bromelain was also studied in the innate immune system, where it could enhance and sustain the process
ATG5↑,
LC3I↑,
Beclin-1↑,
IL2↓, bromelain in vitro experiments resulted in diminished amounts of IL-2, IL-6, IL-4, G-CSF, Gm-CSF, IFN-γ,
IL4↓,
IFN-γ↓,
COX2↓, proprietary bromelain extract could decrease IL-8, COX-2, iNOS, and TNF-α without affecting cell viability.
iNOS↓,
ChemoSen↑, Bromelain may increase the cytotoxicity of cisplatin in the treatment of breast cancer as reported in 2 studies with MDA-MB-231 and 4T1 Breast Tumor cell lines
RadioS↑, The size and weight of tumors in gamma-irradiated EST-bearing mice treated with bromelain decreased significantly with a significant amelioration in the histopathological examination
Dose↝, oral bromelain administration in breast cancer patients (daily up to a dose of 7800 mg)
other↓, The role of bromelain (in combination with papain, sodium selenite and Lens culinaris lectin) has been also tested as a complementary medicine on more than 600 breast cancer patients to reduce the side effects caused by the administration of the adju
Diar↓, Treatment with BJe decreased the appearance of diarrhea and body weight loss.
Weight↑,
NF-kB↓, BJe reduced nuclear NF-κB translocation, p-JNK activation, the pro-inflammatory cytokines release, the appearance of nitrotyrosine and PAR in the colon and reduced the up-regulation of ICAM-1 and P-selectin.
p‑JNK↓,
ICAM-1↓,
*Diar↓, Carvacrol supplementation significantly reduced the incidence of diarrhea and improved the clinical and diarrhea scores in mice (p < 0.05).
*GutMicro↑, Microbiome analysis revealed a significant increase in Proteobacteria and reduction in the abundance of protective bacterial flora in antibiotic-treated and C.
*Dysb↓, Results suggest that CR could potentially be used to control gut dysbiosis and reduce C. difficile infection
| - |
Review, |
Nor, |
NA |
|
|
|
- |
Review, |
AD, |
NA |
|
|
|
- |
Review, |
asthmatic, |
NA |
|
|
|
*Inflam↓, ic, analgesic, anti-inflammatory,antioxidant, and neuroprotective effects.
*antiOx↑,
*neuroP↑, Carvacrol has exhibited notable neuroprotective effects in experimental models of cognitiveimpairment and neurodegenerative diseases
*BioAv↑, advances in encapsulation andnanotechnology have enhanced its stability and bioavailability
*toxicity↓, Compared to phenol, carvacrol and thymol exhibitsignificantly lower toxicity. This makes carvacrol a safer alternative for various applications, frombiological agents to dietary supplements [
*Pain↓, Pain-Relieving Mechanisms of Car
*TRPV3↑, , carvacrol-induced TRPV3 activation enhances lipolysis in adipocytes via theNRF2/FSP1 a
*NRF2↑,
*Ca+2↑, TRPV3 activation in distal colon epithelial cells elevates intracellular Ca²⁺ levels and stimulates ATP release, implicating carvacrol in gut physiology and signaling
*ATP↑,
*5LO↓, s, including the inhibition of angiotensin-converting enzyme 2 (ACE2), lipoxygenase(LOX), and cyclooxygenase (COX) enzyme
*COX2↓,
PGE2↓, arvacrol’s anti-inflammatory effects involve theinhibition of prostaglandin E₂ (PGE₂) production via COX-2
*hepatoP↑, Carvacrol in Hepatic Protection as Natural Antioxidant
*AntiAg↑, Carvacrol has demonstrated significant antiplatelet activity, highlighting its potential therapeutic role in preventing thrombosis
*Diar↓, s essentialoil exhibited antidiarrheal effects in castor oil-induced diarrhea models, potentially mediated bymechanisms involving Kv channel activation and Ca²⁺ channel inhibition
*cardioP↑, em as promising nutraceutical candidates for alleviatingCVD-related complicat
*other↝, Carvacrol was evaluated for its therapeutic potential in managing erectile dysfunction (ED)associated with aging
*chemoPv↑, Chemopreventive Potential of Carvacrol in Detoxification pathways
*cognitive↑, carvacrol(0.5–2 mg/kg) and thymol significantly improved cognitive function in rats
*AChE↓, potent acetylcholinesterase inhibitory activity (IC₅₀: 158.94 μg/mL)
*GastroP↑, . Gastroprotective Effects of Carvacrol and Mechanism
*eff↑, . When combined with polysorbate 80 as a surfactant, carvacrol was efficiently deliveredto embryonic tissues, maintaining bioavailability during the peri-hatching phase
*BChE↓, acrol. The essential oil rich in carvacrol showedstrong inhibitory effects on AChE and butyrylcholinesterase (BChE) [
*CRP↓, d Phase II clinical trial, asthmatic patients whoreceived 1.2 mg/kg/day of carvacrol for two months showed significant improvements in pulmonaryfunction tests and a notable reduction in C-reactive protein levek
Showing Research Papers: 1 to 5 of 5
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress ⓘ
Catalase↓, 1, GSH↓, 1, HO-1↓, 1, lipid-P↓, 1, MDA↓, 1, ROS↑, 1, SOD↑, 1,
Mitochondria & Bioenergetics ⓘ
XIAP↓, 1,
Core Metabolism/Glycolysis ⓘ
ACSL4↑, 1,
Cell Death ⓘ
APAF1↑, 1, Apoptosis↑, 1, Casp3↓, 1, Casp9↑, 1, Cyt‑c↓, 1, iNOS↓, 1, JNK↓, 1, p‑JNK↓, 1, MAPK↓, 1,
Transcription & Epigenetics ⓘ
other↓, 1,
Protein Folding & ER Stress ⓘ
HSP27↓, 1,
Autophagy & Lysosomes ⓘ
ATG5↑, 1, Beclin-1↑, 1, LC3I↑, 1,
DNA Damage & Repair ⓘ
DNAdam↑, 1, P53↑, 1,
Proliferation, Differentiation & Cell State ⓘ
CD44↓, 1, ERK↓, 1,
Migration ⓘ
β-catenin/ZEB1↓, 1,
Immune & Inflammatory Signaling ⓘ
COX2↓, 1, ICAM-1↓, 1, IFN-γ↓, 1, IL2↓, 1, IL4↓, 1, Imm↑, 1, NF-kB↓, 2, PGE2↓, 1,
Drug Metabolism & Resistance ⓘ
ChemoSen↑, 1, Dose↝, 1, RadioS↑, 1,
Functional Outcomes ⓘ
Weight↑, 1,
Infection & Microbiome ⓘ
Diar↓, 2,
Total Targets: 41
Pathway results for Effect on Normal Cells:
NA, unassigned ⓘ
Dysb↓, 1,
Redox & Oxidative Stress ⓘ
antiOx↑, 1, NRF2↑, 1,
Mitochondria & Bioenergetics ⓘ
ATP↑, 1,
Kinase & Signal Transduction ⓘ
TRPV3↑, 1,
Transcription & Epigenetics ⓘ
other↝, 1,
Migration ⓘ
5LO↓, 1, AntiAg↑, 1, Ca+2↑, 1,
Barriers & Transport ⓘ
GastroP↑, 1,
Immune & Inflammatory Signaling ⓘ
COX2↓, 1, CRP↓, 1, Inflam↓, 2,
Synaptic & Neurotransmission ⓘ
AChE↓, 1, BChE↓, 1,
Drug Metabolism & Resistance ⓘ
BioAv↑, 1, eff↑, 1,
Clinical Biomarkers ⓘ
CRP↓, 1, GutMicro↑, 1,
Functional Outcomes ⓘ
cardioP↑, 1, chemoPv↑, 1, cognitive↑, 1, hepatoP↑, 1, neuroP↑, 1, Pain↓, 2, toxicity↓, 1, Wound Healing↑, 1,
Infection & Microbiome ⓘ
Bacteria↓, 1, Diar↓, 3,
Total Targets: 29
Scientific Paper Hit Count for: Diar, Diarrhea
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1456 State#:% Dir#:1
wNotes=on sortOrder:rid,rpid
Home Page